ESMO 2024 special: Results of interim analysi...

In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Prof. Jose Karam on the results of the LITESPARK-022 study: Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomised phase 3 LITESPARK-022 study.The LI ...  Show more

Prostate surgery in the United Kingdom was the domain of general surgeons for a relatively long time, discover why in this podcast. On the other hand, the UK has been leading the professionalisation and organisation of urological nurses. Both topics (and more) are the major topic ...  Show more

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more

Transcatheter aortic valve replacement (TAVR) has emerged as the preferred treatment for aortic stenosis. However, there is a lack of long-term outcome data for low-risk patients. The 5-year results from the Evolut Low-Risk randomized trial address this gap, offering compelling e ...  Show more

PARP Inhibitors in Advanced Prostate Cancer Care Podcast CME Available: https://auau.auanet.org/node/37321 Host: Jay D. Raman, MD, FACS Guests: Maha Hussain, MD and Ganesh Raj, MD, PhD LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identi ...  Show more

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more